Collegium Pharmaceutical, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Collegium Pharmaceutical, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 210.0 times. Higher than almost all Healthcare companies in United States.
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than 94% of Healthcare companies in United States.
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $449 of operating cash. Higher than 94% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$449Over the last 3 years, every $100 of reported profit came with $449 of operating cash.
Higher than 94% of Healthcare companies in United States.
Self-Funding Ratio
100×+Over the last 3 years its own operating cash covered its investment spending (capex) 210.0 times.
Higher than almost all Healthcare companies in United States.
Cash Locked Ratio
$27For every $100 of sales, $27 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $48 tied up three years earlier.
More money tied up than 59% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$28Sales grew 68% in 3 years; of every extra $100 of sales, $28 became extra profit.
Higher than 56% of Healthcare companies in United States.
Asset Productivity Ratio
+68% / +41%In 3 years sales changed by +68% while total assets changed by +41%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
11.4×Debt due within a year is covered 11.4 times by its yearly operating cash.
Higher than 86% of Healthcare companies in United States.
Cash Cushion Ratio
−56%Debt, after subtracting cash, equals 56% of its market value (net debt).
Lower than 93% of Healthcare companies in United States.
Tangible Assets Ratio
51%Of every $100 the company owns, $51 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 79% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 94% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Collegium Pharmaceutical, Inc. owes $0.85 for every $1 it owns. Net profit fell 9% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
18.5Investors pay $18.5 for every $1 of Collegium Pharmaceutical, Inc.'s yearly profit, lower than 68% of Healthcare companies in United States.
P/B ratio
2.45The share price is 2.45 times Collegium Pharmaceutical, Inc.'s book value per share, lower than 52% of Healthcare companies in United States.
Market cap
$765 MThe total market value of all of Collegium Pharmaceutical, Inc.'s shares at today's price (share price × number of shares), larger than 61% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$312 MWhat Collegium Pharmaceutical, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$9.58Net worth divided by the number of shares. The share price of $23.50 is 2.5 times this, which is the P/B above.
Return on equity (ROE)
17.6%Collegium Pharmaceutical, Inc. earned 17.6% on its shareholders' money over the last year, higher than 89% of Healthcare companies in United States.
Owes vs Owns
0.85×Collegium Pharmaceutical, Inc. owes $0.85 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.
Dividend yield
NoneCollegium Pharmaceutical, Inc. does not currently pay a dividend.
Revenue growth
+24%Revenue rose 24% in the year to Dec 2025, and grew 19% a year on average over 3 years.
Profit growth
-9%Net profit fell 9% in the year to Dec 2025.
Profit margin
8.1%Collegium Pharmaceutical, Inc. keeps $8 of every $100 of revenue as net profit.
Cash quality
5.2×Cash from Collegium Pharmaceutical, Inc.'s business was 5.2× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
2.2×Collegium Pharmaceutical, Inc.'s operating profit covered its interest costs 2.2 times in the year to Dec 2025.
Cash vs debt
Net debtCollegium Pharmaceutical, Inc. had $428 M more debt than cash (net debt) at Dec 2025.
Questions
What is Collegium Pharmaceutical, Inc.'s P/E ratio?
Investors pay $18.5 for every $1 of Collegium Pharmaceutical, Inc.'s yearly profit, lower than 68% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Collegium Pharmaceutical, Inc.: $765 M ÷ $312 M (30 Jun 2026) = 2.5.
What is Collegium Pharmaceutical, Inc.'s return on equity?
Collegium Pharmaceutical, Inc. earned 17.6% on its shareholders' money over the last year, higher than 89% of Healthcare companies in United States.
How much does Collegium Pharmaceutical, Inc. owe compared with what it owns?
Collegium Pharmaceutical, Inc. owes $0.85 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.
Does Collegium Pharmaceutical, Inc. pay a dividend?
No. Collegium Pharmaceutical, Inc. does not currently pay a dividend.
Is Collegium Pharmaceutical, Inc.'s revenue growing?
Revenue rose 24% in the year to Dec 2025, and grew 19% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.